---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000158"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-08-24T23:59:59+00:00"
generated_at: "2026-06-11T04:22:38.221870+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Centessa's oral OX2R agonist ORX750 preclinically reduces cataplexy and promotes wakefulness in narcolepsy mouse model

## Summary
- ORX750 is a potent full agonist at human OX2R (EC50=0.11 nM) with >9,800-fold selectivity over OX1R.
- In orexin/ataxin-3 narcolepsy mice, ORX750 increased wakefulness and consolidated wakefulness dose-dependently.
- At 0.3 mg/kg, latency to sleep was 2.3 h (vs 0.69 h vehicle) and latency to cataplexy was 2.7 h (vs 1.3 h vehicle).
- ORX750 also increased EEG gamma power during wakefulness and reduced cataplexy occurrences in active-phase EEG/EMG assays.
- Company will present abstract at World Sleep Congress 2023 on October 25, 2023.

## SEC filing metadata
- accession: 0001847903-23-000158
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-08-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/0001847903-23-000158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/cnta-20230822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000158
- JSON: https://secwatch.observer/filing/0001847903-23-000158.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.